

the presence of different concentrations of unlabeled L13, L19, G₀, and tRNA^{ser}. The level of binding of L13 was calculated as the ratio of the percentage of bound radiolabeled L13 in the presence of other ligands over that obtained in the absence of these ligands. The values are the means of triplicate experiments. A value of 100% indicated that there was no competition between the binding of L13 and the other ligand molecules to HCMV.

[Figure 3.] Figures 3A-3D. Effect of the ligands on plaque formation (Figure 3A and Figure 3C) and particle production (Figure 3B and Figure 3D). 1x10⁵ pfu/ml HCMV (AD169) or HSV-1 (F) was incubated in DMEM media alone or in the presence of different concentrations of G₀, L13, L19 at 37°C for 15 mins before used to infect HFFs at MOI of 0.005 (for plaque assay) or 0.3 (for titer assay). The levels of viral titer and plaque formation were calculated as the ratio of the titers and plaque numbers assayed from experiments with HCMV incubated in the presence of the ligands over those from experiments with HCMV incubated in DMEM alone, respectively. The values are the means of triplicate experiments.--

NE
Page 4, line 29, to page 5, line 6, replace with the following rewritten paragraph:

--[Figure 9] Figures 9A-9D. Effect of the ligands on plaque formation (A and C) and particle production (B and D) of HCMV (AD169) (A and B) and herpes simplex virus 1 (F) (C and D) in human foreskin fibroblasts (HFFs). 1x10⁵ PFU/ml HCMV (AD169) or HSV-1 (F) was incubated in DMEM media alone or in the presence of different concentrations of G₀, L31, L66 at 37°C for 15 mins before being used to infect HFFs at MOI of 0.02 (for plaque assay) or 0.5 (for titer assay). The levels of viral titer and plaque formation were calculated as the ratio of the titers and plaque numbers assayed from experiments with HCMV incubated in the presence of the ligands over those from experiments with HCMV incubated in DMEM alone, respectively. The values are the means from triplicate experiments.--

IN THE CLAIMS

Please replace the pending claims with the correspondingly numbered claims below. Claims amended herein are noted by the text in parentheses. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment; captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

✓
Cancel claims 2-5, 7, 9, 11, 17-18, 20, 22, and 24.